A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers

AIMS: To examine whether tamper-resistant formulations (TRFs) of tapentadol hydrochloride ER 50 mg (TAP50) and tapentadol hydrochloride 250 mg (TAP250) could be converted into forms amenable to intranasal (Study 1) or intravenous abuse (Study 2). DESIGN: Randomized, repeated-measures study designs w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vosburg, Suzanne K., Jones, Jermaine D., Manubay, Jeanne M., Ashworth, Judy B., Shapiro, Douglas Y., Comer, Sandra D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664924/
https://ncbi.nlm.nih.gov/pubmed/23316699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/add.12114
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller